Itaconate as an inflammatory mediator and therapeutic target in cardiovascular medicine

Biochem Soc Trans. 2021 Nov 1;49(5):2189-2198. doi: 10.1042/BST20210269.

Abstract

Inflammation is a critical component of cardiovascular disease (CVD), encompassing coronary artery disease (CAD), cerebrovascular events and heart failure and is the leading cause of mortality worldwide. In recent years, metabolism has been placed centrally in the governance of the immune response. Termed immunometabolism, immune cells adapt cellular metabolic pathways to meet demands of activation and thus function. This rewiring influences not only the bioenergetics of the cell but altered metabolites act as signalling molecules to regulate cellular response. In this review, we focus on the TCA cycle derivative, itaconate, as one such metabolite with promising immunomodulatory and therapeutic potential in inflammatory cardiovascular disease.

Keywords: cardiovascular disease; immunometabolism; inflammation; itaconate; metabolic reprogramming; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers / metabolism
  • Cardiovascular Diseases / metabolism*
  • Energy Metabolism
  • Glycolysis
  • Humans
  • Inflammation / metabolism
  • Inflammation Mediators / metabolism*
  • Kelch-Like ECH-Associated Protein 1 / metabolism
  • NF-E2-Related Factor 2 / metabolism
  • Succinate Dehydrogenase / antagonists & inhibitors
  • Succinates / metabolism*

Substances

  • Biomarkers
  • Inflammation Mediators
  • KEAP1 protein, human
  • Kelch-Like ECH-Associated Protein 1
  • NF-E2-Related Factor 2
  • NFE2L2 protein, human
  • Succinates
  • Succinate Dehydrogenase
  • itaconic acid